سعر ميجيسترون 150مجم/مل فيال عضل 2022

Medroxyprogesterone 150 mg/ml injection for intramuscular use, single vial (contraceptive).

• Prevention of pregnancy in females of reproductive potential.Population: Females of reproductive potential (not indicated before menarche)DailyMed (U.S. National Library of Medicine)

• Common: weight gain over 10 lb (37.7% at 24 months), headache 16.5%, abdominal pain/discomfort 11.2%, nervousness 10.8%, dizziness 5.6%, decreased libido 5.5%, menstrual irregularities (amenorrhea in about 55% at 12 months).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Active thrombophlebitis or current/past thromboembolic disorders or cerebrovascular disease; known or suspected breast cancer; hypersensitivity to medroxyprogesterone acetate or any ingredient; significant liver disease; undiagnosed vaginal bleeding.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: prolonged use may cause significant loss of bone mineral density, greater with longer use and possibly not completely reversible; not recommended as a long-term (over 2 years) method unless others are inadequate.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Other warnings: thromboembolic disorders, meningioma, ectopic pregnancy, anaphylaxis, liver function abnormalities, depression, bleeding irregularities (amenorrhea common), weight gain, decreased glucose tolerance, delayed return of fertility (among women who conceive, median time to conception about 10 months after the last injection); does not protect against sexually transmitted infections.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inducersDrugs or herbal products that induce CYP3A4 may decrease medroxyprogesterone acetate plasma concentrations.DailyMed (U.S. National Library of Medicine)

• There is no use for contraception in pregnancy; discontinue if pregnancy occurs. Studies have not found an increased risk of birth defects after progestin exposure before conception or in early pregnancy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Medroxyprogesterone acetate is detectable in breast milk without apparent adverse effect on milk or infants; in exclusively breastfeeding mothers, start during or after the 6th postpartum week.International label, same formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.